Compare Vanguard Total World Stock Index Fund ETF (VT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total World Stock Index Fund ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Total World Stock Index Fund ETF trades at $159.46 (market cap $101.70B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.95B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Total World Stock Index Fund ETF for 53 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| VT | ZBH | |
|---|---|---|
Market Cap | $101.70B | $16.95B |
Volume | 1,783,794 | 2,505,240 |
Sector | Broad Market / Factor | Health |
52-Week High | $162.39 | $103.98 |
52-Week Low | $134.19 | $79.58 |
Typical Hold Time | 53 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VT trades at $159.64, down 0.66% on the day, with technical indicators showing a bullish bias in moving averages while oscillators remain neutral. The ETF maintains strong global diversification with over 9,700 stocks across developed and emerging markets. Recent news highlights VT's competitive positioning against international-focused ETFs, with Seeking Alpha maintaining a Buy rating and targeting 6-10% returns over the next 6-12 months.
VT offers comprehensive global equity exposure with a low 0.06% expense ratio, though key financial ratios remain unavailable. The outlook remains positive for long-term diversification, with risks including currency fluctuations and geopolitical tensions. Institutional activity shows mixed signals with both position increases and decreases reported in recent quarters.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $8.23B in 2025, though net margins have compressed from 13.84% in 2023 to 8.56%. Analyst consensus is mixed with 40% buy ratings but a $103.11 price target suggesting 16.5% upside. Recent news highlights dividend declarations and leadership promotions aimed at accelerating commercial transformation.
ZBH presents a value opportunity with reasonable valuation multiples (P/E 21.48, P/S 2.04) and consistent earnings outperformance, but faces headwinds from margin pressure and technical weakness. The stock's investment case hinges on execution of growth initiatives amid competitive and debt-related risks, with current levels offering entry near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
